Drug Reduces Airway Mucus In Preclinical Asthma Model

February 20, 2008 – 6:52 am | posted in Respiratory / Asthma

Inverseon, Inc. announces the publication of a rapid communication of groundbreaking research led by Professor Richard Bond of the University of Houston, Inverseon’s Scientific Founder. In the March article by Nguyen, et. al., in the American Journal of Respiratory Cell and Molecular Biology 2008; 38: 256-262, entitled, “Chronic Exposure to Beta-Blockers Attenuates Inflammation and Mucin Content in a Murine Asthma Model,” airway mucus hypersecretion and inflammation were almost completely reversed upon treatment with certain beta blockers. The Journal commented that, “This research may result in a paradigm shift in the treatment of asthma. This research demonstrates the importance that duration of therapy has on clinical and physiologic responses.”

“It is gratifying to see these findings, which were originally described in Prof. Bond’s laboratory, confirmed in a respected independent laboratory,” commented William J. Garner, MD, Chairman of Inverseon.

About Inverseon, Inc.

Inverseon’s product development programs target significant unmet medical needs and major market opportunities in chronic pulmonary diseases such as asthma, COPD and pulmonary hypertension. Inverseon was founded based on the original work of Prof. Richard Bond of the University of Houston. Professor Bond termed the effects “Paradoxical Pharmacology,” based on the divergence of acute versus chronic effects of certain drugs in chronic diseases. For further information, please visit Inverseon’s website at http://www.inverseon.com.

Forward-Looking Statement

This press release may contain forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential” or “continue,” the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events, or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.

Inverseon, Inc.

ShareThis

Tags: Airway, Asthma, Biochemistry, Biology, Drug, Model, Mucus, Preclinical, Reduces, Respiratory